Active Funding Opportunities:
Notice of Special Interest (NOSI)
NOT-HG-24-012: Advancing Genomic Technology Development for Research and Clinical Application (R01, R21, R42, R43, R44)
*First due date is February 5th, 2024; Expiration date is January 10th, 2027*
The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications focused on developing novel laboratory-focused tools and technologies that enable new lines of scientific inquiry and clinical applications in human genomics.
Notice of Funding Opportunity (NOFO)
RFA-HG-24-013: NHGRI Technology Dvelopment Coordinating Center (U24)
*Letter of Intent due date is March 1st, 2024; Application due date is April 2nd, 2024; Expiration date is April 3rd, 2024*
The National Human Genome Research Institute (NHGRI) is announcing a Notice of Funding Opportunity (NOFO) to encourage applications for the NHGRI Technology Development Coordinating Center. The Coordinating Center will enable opportunities for collaborations among grantees of the Genome Technology Program, and improve dissemination of technology advances and resources.
Inactive Funding Opportunities:
Notice of Special Interest (NOSI)
- NOT-HG-21-018: Advancing Genomic Technology Development for Research and Clinical Application
RFAs
- RFA-HG-21-006: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R01 Clinical Trial not Allowed)
- RFA-HG-21-007: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 Clinical Trial not Allowed)
- RFA-HG-21-008: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44 Clinical Trial not Allowed)
- RFA-HG-21-001: Technology Development for Single-Molecule Protein Sequencing and Single-Cell Proteome Analysis (R01 Clinical Trial not allowed)
- RFA-HG-21-002: Technology Development for Single-Molecule Protein Sequencing (R21 Clinical Trial not allowed)
- RFA-HG-20-014: Novel Synthetic Nucleic Acid Technology Development (R01 Clinical Trial not allowed)
- RFA-HG-20-015: Novel Synthetic Nucleic Acid Technology Development (R21) (Clinical Trial not allowed)
- RFA-HG-20-016: Novel Synthetic Nucleic Acid Technology Development (R43/R44) (Clinical Trial Not Allowed)
- RFA-HG-20-019: NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed)
- RFA-HG-18-001: Novel Nucleic Acid Sequencing Technology Development (R01 Clinical Trial Not Allowed)
- RFA-HG-18-002: Novel Nucleic Acid Sequencing Technology Development (R21 Clinical Trial Not Allowed)
- RFA-HG-18-003: Novel Nucleic Acid Sequencing Technology Development (R43/R44 Clinical Trial Not Allowed)
PARs
- PAR-21-247: Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial Not Allowed)
- PAR-18-777: Novel Genomic Technology Development (R01 Clinical Trial Not Allowed)
- PAR-18-778: Novel Genomic Technology Development (R21 Clinical Trial Not Allowed)
- PAR-18-779: Novel Genomic Technology Development (R43/R44 Clinical Trial Not Allowed)
For more funding opportunities please visit NHGRI Research Funding
Updated 01/31/2024
